Table 3.

Follow up data comparison between pediatric and adult groups

Follow up parameters	Total (n=25), n (%)	Adults (n=18), n (%)	Pediatric group (n=7), n (%)	P
Follow up duration (months)	55.7±37.5	60.3±29.1	43.9±54.7
	64 (7-147)	67 (11-120)	15 (7-147)
Residual shunt at last follow up	3 (15)	2 (11.1)	1 (14.3)	0.826
Antiplatelet/anticoagulant use
Aspirin monotherapy	4 (16)	0	4 (57.1)	0.001
Aspirin + clopidogrel	19 (76)	17 (94.4)	2 (28.6)
Aspirin + warfarin	2 (8)	1 (5.6)	1 (14.3)
Aspirin duration (months)	9.5 (6-18)	11 (6-18)	6 (6-12)	0.385
Clopidogrel duration (months)	6 (2-12)	6 (3-12)	2	0.111
Late complication
Device thrombosis	1 (4)	1 (5.6)	0
Deep vein thrombosis	1 (4)	0	1 (14.3)
Bleeding manifestations	2 (8)	1 (5.6)	1 (14.3)
Late embolization	0	0	0
Erosion	0	0	0
Late arrhythmias	0	0	0
Thrombo embolic events	0	0	0
Headaches	0	0	0